kinas
inhibitor
viral
polymeras
inhibitor
b
r
c
studi
examin
impact
roscovitin
cyclindepend
kinas
inhibitor
cdki
enter
phase
ii
clinic
trial
influenza
virus
iav
antivir
mechan
result
illustr
roscovitin
inhibit
multipl
subtyp
influenza
strain
dosedepend
includ
ic
valu
mm
respect
moreov
roscovitin
suppress
gene
transcript
genom
replic
step
viral
life
cycl
mechanist
studi
indic
roscovitin
reduc
viral
polymeras
activ
bound
specif
viral
protein
fluoresc
polar
assay
fp
surfac
plasmon
reson
spr
therefor
believ
roscovitin
inhibitor
prospect
antivir
agent
develop
therapeut
treatment
influenza
viru
infect
human
influenza
one
common
infecti
diseas
affect
billion
peopl
around
globe
annual
tend
come
winter
season
often
time
swing
across
countri
cours
month
epidem
caus
signific
morbid
mortal
patient
may
develop
sever
respiratori
infect
pneumonia
mening
etc
addit
direct
impact
viru
influenza
also
may
bring
complic
bacteri
superinfect
cardiovascular
event
caus
numer
infect
individu
death
new
strain
influenza
viru
transmit
anim
human
viru
often
evolv
rapidli
time
make
vaccin
develop
difficult
gener
hand
continu
antigen
drift
antigen
shift
influenza
viral
surfac
glycoprotein
vaccin
formul
one
subtyp
influenza
mayb
ineffect
follow
year
due
new
epidem
strain
henc
human
influenza
virus
continu
pose
import
threat
human
health
modern
societi
variou
prevent
treatment
method
influenza
wide
studi
around
world
current
use
antivir
drug
regard
first
line
defens
influenza
epidem
pandem
channel
inhibitor
amantadin
neuraminidas
na
inhibitor
zanamivir
oseltamivir
fdaapprov
antivir
drug
howev
class
drug
face
increas
drug
resist
challeng
thu
despit
util
antivir
drug
novel
antivir
demand
due
emerg
advers
effect
increas
resist
new
influenza
strain
exampl
us
fda
approv
xofluza
baloxavir
marboxil
influenza
viru
polymeras
inhibitor
treatment
influenza
symptom
less
h
peopl
age
explor
antivir
activ
exist
drug
known
safeti
profil
feasibl
costsav
exampl
includ
cyclindepend
kinas
inhibitor
cdki
instanc
inhibitor
suppress
replic
sever
virus
human
papillomaviru
hepat
b
viru
flavopiridol
dinaciclib
abil
replic
influenza
viru
inhibit
host
rna
polymeras
ii
rnapii
activ
result
viral
mrna
transcript
decreas
roscovitin
purin
deriv
cdki
inhibit
report
roscovitin
block
replic
varieti
virus
vitro
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
prove
high
safeti
human
clinic
trial
research
effect
cancer
studi
first
identifi
inhibitori
activ
roscovitin
influenza
viru
iav
replic
yet
report
past
investig
demonstr
roscovitin
specif
bound
highli
conserv
region
inhibit
viral
gene
transcript
genom
replic
find
suggest
roscovitin
promis
inhibitor
therapeut
treatment
influenza
viru
infect
roscovitin
purchas
bidepharm
shanghai
china
puriti
zanamivir
peramivir
purchas
sigmaaldrich
st
loui
mo
usa
synthet
puriti
laboratori
madin
darbi
canin
kidney
mdck
human
embryon
kidney
cell
human
lung
bronchial
epitheli
cell
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
penicillinstreptomycin
iav
subtyp
includ
store
c
plasmid
ppolifluc
firefli
luciferas
report
plasmid
gener
suppli
professor
bojian
zheng
univers
hong
kong
hong
kong
china
hrluctk
renilla
luciferas
plasmid
purchas
promega
madison
wi
usa
mdck
cell
infect
virus
tcid
plate
c
h
supernat
replac
roscovitin
gradient
dilut
contain
mgml
tpck
sigmaaldrich
mo
usa
h
pi
cytopath
effect
cpe
virusinfect
cell
observ
microscopi
antivir
level
detect
mttbase
assay
mdck
cell
treat
moi
h
follow
addit
sigmaaldr
mo
usa
mix
medium
contain
mgml
tpcktrypsin
sigmaaldrich
mo
usa
penicillinstreptomycin
liquid
microcrystallin
cellulos
roscovitin
serial
concentr
well
continu
cultur
h
condit
co
c
mdck
cell
plate
infect
virus
moi
describ
h
incub
cell
fix
paraformaldehyd
min
block
bsa
h
incub
nucleoprotein
np
antibodi
c
overnight
cell
incub
fitclabel
secondari
antibodi
h
santa
cruz
ca
usa
dapi
nuclear
dye
ad
stain
min
fluoresc
observ
fluoresc
microscop
nikon
japan
mdck
cell
infect
virus
moi
h
follow
addit
roscovitin
differ
concentr
incub
cell
lyse
ripa
rna
isol
kit
antibodi
shown
tabl
qrtpcr
primer
sequenc
shown
tabl
previou
report
cell
infect
virus
moi
h
treat
roscovitin
concentr
mm
differ
time
interv
turn
h
h
h
h
h
western
blot
quantit
realtim
pcr
use
analyz
result
minireplicon
system
use
detect
cellular
rnadepend
rna
polymeras
activ
influenza
viru
ng
pa
np
plasmid
ng
ppolifluc
firefli
luciferas
report
plasmid
togeth
ng
hrluctk
renilla
luciferas
plasmid
transfect
cell
lipofectamin
h
transfect
supernat
replac
fresh
medium
contain
roscovitin
cultur
h
cell
lyse
min
luciferas
activ
measur
luciferas
report
gene
detect
kit
provid
promega
madison
wi
usa
ml
serial
dilut
reaction
buffer
mm
kcl
mm
dtt
mm
edta
mm
hepe
dmso
ph
ad
black
plate
fitclabel
jena
bioscienc
germani
cap
analog
detect
probe
nm
probe
incub
serialdilut
room
temperatur
min
roscovitin
gradient
dilut
ad
plate
min
plate
measur
infinit
pro
tecan
usa
protein
structur
deriv
rcsb
protein
data
bank
pdb
code
bind
domain
ligand
assign
amber
forc
field
charg
respect
dock
perform
ucsf
dock
electrostat
interact
van
der
waal
forc
roscovitin
bind
site
acquir
constitut
grid
score
optim
model
obtain
cluster
analysi
rmsd
threshold
spr
data
roscovitin
bind
protein
analyz
plexarray
ht
system
roscovitin
fix
sensor
chip
extern
photocrosslink
protein
inject
nm
nm
nm
flow
ml
contact
time
dissoci
time
run
buffer
pb
phosphat
buffer
glycinehcl
ph
data
export
plexera
de
softwar
bia
evolut
softwar
use
adjust
data
calcul
k
valu
statist
analys
data
carri
use
graphpad
prism
softwar
experi
perform
three
time
result
express
mean
standard
deviat
sd
statist
signific
two
group
analyz
ttest
pvalu
regard
statist
signific
studi
antivir
activ
roscovitin
first
examin
effect
roscovitin
cell
viabil
highest
concentr
evalu
cytotox
assay
mm
roscovitin
reduc
cell
viabil
mdck
cell
concentr
fig
besid
roscovitin
show
broadspectrum
inhibit
differ
subtyp
viru
strain
includ
tabl
ic
approxim
mm
differ
viru
strain
impli
futur
deriv
roscovitin
would
improv
antivir
properti
maintain
lower
cytotox
effect
conduct
experi
viru
strain
compar
viral
infect
group
cytopath
effect
cpe
decreas
significantli
fig
besid
number
plaqu
express
viral
mrna
fluoresc
spot
show
analog
downward
trend
dosedepend
manner
fig
furthermor
h
h
postinfect
express
viral
np
protein
reduc
obvious
fig
simultan
obviou
reduct
progeni
viral
particl
roscovitinetr
supernat
observ
plaqu
assay
fig
result
demonstr
roscovitin
could
effect
inhibit
influenza
viru
replic
hemagglutinin
ha
na
viral
surfac
glycoprotein
relat
viru
entri
releas
stage
respect
therefor
exert
three
experi
hemagglutinin
inhibit
assay
pseudoviru
neutral
assay
na
inhibit
assay
confirm
whether
roscovitin
effect
viral
entri
releas
result
demonstr
roscovitin
could
prevent
red
blood
cell
hemagglutin
fig
pseudoviru
infect
indic
effect
viru
entri
fig
meanwhil
signific
inhibit
effect
observ
enzym
activ
na
impli
compound
hardli
affect
viru
releas
fig
therefor
estim
roscovitin
might
suppress
influenza
viru
mechan
first
timeofaddit
assay
perform
detect
antivir
stage
roscovitin
treatment
postinfect
entireinfect
inhibit
effect
roscovitin
improv
obvious
especi
postinfect
mode
inconspicu
effect
pretreat
preinfect
mode
fig
suggest
compound
exert
inhibit
effect
viru
enter
target
cell
report
previous
one
life
cycl
influenza
viru
around
h
divid
three
main
step
viru
entri
h
viral
gene
transcript
genom
replic
h
progeni
viral
releas
h
explor
period
viral
life
cycl
disturb
roscovitin
cell
treat
roscovitin
differ
time
interv
one
viral
life
cycl
fig
shown
fig
c
compound
could
greatli
lessen
express
level
viral
protein
mrna
h
h
time
interv
indic
block
viral
gene
transcript
genom
replic
stage
viral
rnadepend
rna
polymeras
rdrp
play
import
role
viral
genom
transcript
replic
stage
conjectur
antivir
abil
relev
interfer
viral
rdrp
activ
report
previous
drug
inhibit
host
rnapii
show
antiinfluenza
activ
treatment
host
factor
inhibitor
process
influenza
viru
snatch
structur
host
premrna
synthes
rnapii
affect
therefor
suppos
roscovitin
may
exert
antiviru
inhibit
rnapii
activ
confirm
explor
phosphoryl
level
carboxytermin
domain
ctd
estim
effect
rnapii
shown
fig
roscovitin
play
weakli
inhibit
abil
domain
mm
wherea
viral
protein
express
markedli
reduc
mm
therefor
consid
major
antivir
effect
might
target
viru
inhibit
activ
rnapii
next
conduct
minireplicon
system
cellular
level
viral
rdrp
activ
assay
polymeras
basic
protein
polymeras
basic
protein
polymeras
acid
protein
pa
np
plasmid
transfect
cell
act
viral
rdrp
np
complex
report
plasmid
would
transcrib
correspond
viral
mrna
mediat
luciferas
express
show
fig
activ
report
gene
decreas
dosedepend
manner
reveal
roscovitin
inhibit
polymeras
activ
viral
rdrp
one
part
viral
ribonucleoprotein
vrnp
transloc
nucleu
primari
role
vrnp
transcrib
viral
mrna
product
viral
protein
replic
fulllength
complementari
genom
rna
crna
amplif
vrna
gener
progeni
vrnp
therefor
synthesi
vrna
crna
affect
activ
viral
rdrp
cut
depict
fig
signific
inhibitori
effect
synthesi
crna
vrna
observ
taken
togeth
result
reveal
roscovitin
block
influenza
viral
rdrp
activ
investig
antivir
mechan
conduct
seri
experi
associ
capsnatch
process
rdrp
involv
domain
express
purifi
domain
fig
fp
assay
use
detect
interact
roscovitin
protein
depict
fig
bind
abil
specif
verifi
firstli
unlabel
posit
control
use
fp
assay
found
roscovitin
suppress
interact
dosedepend
manner
fig
next
use
spr
assay
high
sensit
confirm
result
bind
inhibitor
use
posit
control
accord
plexera
de
analyz
k
valu
roscovitin
mm
mm
fig
fig
overal
data
demonstr
roscovitin
could
strongli
interact
next
investig
amino
acid
bind
site
protein
via
molecular
dock
structur
consist
previous
describ
complex
found
roscovitin
could
bind
domain
imidazol
ring
benzen
ring
pp
interact
also
hydrophob
interact
fig
summari
present
result
indic
roscovitin
strong
interact
possibl
drug
candid
target
rapid
evolv
stealthi
spread
mechan
differ
subtyp
influenza
essenti
explor
possibl
antivir
chemic
virus
meanwhil
novel
antivir
drug
develop
import
complementari
tool
addit
vaccin
aim
improv
therapeut
effici
reduc
drug
resist
howev
drug
develop
expens
riski
laborintens
timeconsum
process
usual
take
year
averag
cost
billion
dollar
complet
develop
process
therefor
indispens
exploit
altern
use
exist
drug
market
approv
indic
diseas
well
drug
candid
clinic
trial
roscovitin
report
act
wide
varieti
cancer
cell
line
induc
apoptosi
moreov
current
consid
potenti
drug
treat
neurodegen
retin
degener
diseas
lung
inflamm
kidney
diseas
besid
compound
also
shown
inhibit
hsv
hiv
infect
thu
regard
effici
potenti
drug
candid
paper
focus
antivir
effect
roscovitin
iav
demonstr
antivir
activ
promis
inhibitor
gener
iav
possess
singlestrand
eightseg
rna
genom
neg
polar
vrna
accomplish
one
life
cycl
includ
viral
attach
entri
gene
transcript
genom
replic
packag
progeni
virus
releas
period
viru
entri
host
cell
vrnp
complex
import
nucleu
transcript
replic
take
place
vrnp
complex
constitut
core
viru
consist
rdrp
np
vrna
segment
repres
minim
transcript
replic
machineri
influenza
rdrp
iav
highli
conserv
among
strain
subtyp
evolut
new
drug
class
antivir
therapi
patient
influenza
rdrp
inhibitor
character
continu
effect
activ
great
patient
complianc
instanc
xofluza
inhibit
viral
replic
target
endonucleas
function
encod
pa
subunit
viral
rdrp
approv
fda
octob
repres
novel
mechan
action
studi
approv
almost
two
decad
articl
found
roscovitin
exert
antivir
effect
target
viru
competit
inhibitor
could
diminish
combin
fig
subunit
one
part
rdrp
play
critic
role
initi
transcript
bind
cap
domain
host
premrna
call
capsnatch
process
subunit
capbind
domain
residu
respons
bind
abil
consid
valid
target
develop
new
antiinfluenza
compound
present
broadspectrum
antiinfluenza
activ
disrupt
capbind
activ
furthermor
antivir
may
consider
minim
emerg
escap
mutant
urgent
indispens
edg
new
devast
pandem
accord
studi
roscovitin
might
influenc
function
exert
antivir
activ
fp
assay
next
spr
assay
use
confirm
result
bind
abil
roscovitin
approxim
stronger
posit
compound
inhibitor
report
previouli
fig
fig
molecular
dock
studi
demonstr
bound
capbind
pocket
via
residu
fig
consist
part
residu
summari
studi
show
strong
evid
potent
antiinfluenza
activ
roscovitin
vitro
roscovitin
disturb
viral
replic
target
viral
conserv
site
notabl
drug
candid
roscovitin
gone
sever
phase
ii
clinic
trial
good
safeti
profil
cancer
therapi
plenti
antivir
activ
studi
conduct
roscovitin
well
thu
explor
therapeut
effect
roscovitin
treatment
influenza
feasibl
promis
furthermor
reinvestig
exist
kinas
inhibitor
potenti
antivir
find
potenti
mechan
may
provid
wide
applic
prospect
viral
infect
diseas
influenza
viru
infect
well
come
pandem
diseas
caus
anoth
rna
viru
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
